Exosome Diagnostics Announces Data Demonstrating ExoIntelliScore Prostate Accurately Predicted Gleason Score, Pathologic Stage And Tumor Volume In Patients With Prostate Cancer

VIENNA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, presented new positive data from a clinical study for the company’s novel, urine-based prostate cancer liquid biopsy, ExoIntelliScore™ Prostate (formally referred to as Exo106). The data demonstrated that ExoIntelliScore Prostate accurately predicted in pre-radical prostatectomy (RP) urine samples of patients with prostate cancer, objective clinical features present in RP specimens and also provided initial improved discrimination of RP Gleason Score 4+3, a subset of patients at elevated risk for aggressive disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news